BioSpace News Archive

BioArctic AB announced that the US Patent and Trademark Office has granted BioArctic a new platform patent for a technology for transporting biopharmaceuticals across the blood-brain barrier.

Lytix Biopharma, a Norwegian immuno-oncology company, announces site activation for the ATLAS-IT-05 study in three European countries.

Singleron Biotechnologies announced their participation in the upcoming 64th American Society of Hematology Annual Meeting & Exposition in New Orleans, LA.

LumiraDx Limited, a next-generation point of care diagnostics company, announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings.

Sentinel CH. SpA announced the launch of SENTiNAT® 200, the fully automated sample to result system, and STAT-NAT® SN200 Real-Time PCR assays for the quantitative detection of 10 viruses.

EpiEndo Pharmaceuticals, the clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD patients.

Apollo Therapeutics, a portfolio biopharmaceutical company focusing on translational biology and drug development, and The Institute of Cancer Research, London, a world-leading cancer research organisation, announce they have entered into a strategic collaboration to discover and develop new cancer medicines.

Lumos Pharma, Inc., announced that interim results met expectations for its Phase 2 OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate pediatric growth hormone deficiency who screened PEM-positive utilizing Lumos’s predictive enrichment marker strategy.

ProKidney Corp. announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments.

DENTSPLY SIRONA Inc. announced its financial results for the third quarter of 2022.